The goal of cellular transplantation is to allow long-term function of the grafted cells using minimal host immunosuppression. To this end, the major strategies to implant cells and tissues are through: (i) the pretreatment of the graft to reduce tissue immunogenicity; (ii) the application of immunoisolation technologies to prevent host sensitization to implanted cells; and (iii) the induction of immunological tolerance to the donor tissues. Further, a major dilemma facing clinical tissue grafting is the shortage of donor tissue for transplantation. This problem requires the consideration of tissues from other species (xenografts) as a potential source of donor material. In light of these issues, the focus of this discussion is on the T cell-dependent response to allogeneic and xenogeneic transplants and the implications of this reactivity on the field of cellular replacement therapy.
AebischerP.; TrescoP.; WinnS.; JaegerC.; GreeneL.Long term cross-species brain transplantation of a polymer-encapsulated dopamine-secreting cell line.Exp. Neurol.126: 1; 1991.
2.
AlterB.J.; BachF.H.Cellular basis of the proliferative response of human T cells to mouse xenoantigens.J. Exp. Med.171: 333–338; 1990.
3.
AuchinclossH.J.Xenogeneic transplantation: A review.Transplantation46: 1–20; 1988.
4.
AuchinclossJ.H.; LeeR.; SheaS.; MarkowitzJ.S.; GrusbyM.J.; GlimcherL.H.The role of “indirect” recognition in initiating rejection of skin grafts from major histocompatibility complex class II-deficient mice.Proc. Natl. Acad. Sci. USA90: 3373–3377; 1993.
5.
Barzaga-GilbertE.; GrassD.; LawrenceS.; PetersonP.; LacyE.; EngelhardV.Species specificity and augmentation of responses to class II major histocompatibility complex molecules in human CD4 transgenic mice.J. Exp. Med.175: 1707–1715; 1992.
6.
BenichouG.; TakizawaP.; OslonC.; McMillanM.; SercarzE.Donor MHC peptides are presented by recipient MHC molecules during graft rejection.J. Exp. Med.175: 3038; 1992.
7.
BowenK.; AndrusL.; LaffertyK.Successful allotransplantation of mouse pancreatic islets to nonimmunosuppressed recipients.Diabetes29(Suppl. 1): 98–104; 1980.
8.
BowenK.; ProwseS.; LaffertyK.Reversal of diabetes by islet transplantation: Vulnerability of the established allograft.Science213: 1261–1262; 1981.
9.
CarelJ.; SchreiberR.D.; FalquiL.; LacyP.E.Transforming growth factor β decreases the immunogenicity of rat islet xenografts (rat to mouse) and prevents rejection in association with treatment of the recipient with a monoclonal antibody to interferon γ.Proc. Natl. Acad. Sci. USA87: 1990.
10.
ChabotJ.; WeberC.; HardyM.; RiveraS.; Bailey-BraxtonD.; StrausbergL.; WoodM.; ChowJ.; Pi-SunyerF.; ReemtsmaK.Synergy of ALS and UV-B in prolongation of primate-to-mouse islet xenograft survival.Transplant. Proc.19: 1160–1165; 1987.
11.
ChenC.; GaultA.; ShenL.; NabaviN.Molecular cloning and expression of early T cell costimulatory molecule-1 and its characterization as B7-2 molecule.J. Immunol.152: 4929–4936; 1994.
12.
ClaytonL.K.; SiehM.; PiousD.A.; ReinherzE.L.Identification of residues affecting class II vs.HIV-1 gp120 binding. Nature339: 548; 1989.
13.
CollinsM.K.L.Species specificity of interleukin 2 binding to individual receptor components.Eur. J. Immunol.19: 1517–1520; 1989.
14.
CoulombeM.; GillR.G.Tolerance induction to cultured islet allografts. I. Characterization of the tolerant state.Transplantation57: 1195–1200; 1994.
15.
DanielD.; GillR.; SchlootN.; WegmannD.Adoptive transfer of diabetes by insulin-specific T cells isolated from NOD mice.Eur. J. Immunol.25: 1056–1062; 1995.
16.
DesaiN.M.; BassiriH.; OdoricoJ.S.; KollerB.H.; SmithiesO.; NajiA.; BarkerC.F.; MarkmannJ.F.Pancreatic islet allograft and xenograft survival in CD8+ T-lymphocyte-deficient recipients.Transplant. Proc.25: 961–962; 1993.
17.
FangmannJ.; DalchauR.; FabreJ.Rejection of skin allografts by indirect allorecognition of donor class I MHC peptides.J. Exp. Med.175: 1521; 1992.
18.
FangmannJ.; DalchauR.; SawyerG.; PriestleyC.; FabreJ.Donor MHC peptides are presented by recipient MHC molecules during graft rejection.Eur. J. Immunol.22: 1525; 1992.
19.
FaustmanD.; CoeC.Prevention of xenograft rejection by masking of donor HLA class I antigens.Science252: 1700–1702; 1991.
20.
FaustmanD.; HauptfeldV.; LacyP.; DavieJ.Prolongation of murine islet allograft survival by pretreatment of islets with antibody directed to Ia determinants.Proc. Natl. Acad. Sci. USA78: 5156–5159; 1981.
21.
FaustmanD.; SteinmanR.; GebelH.; HauptfeldV.; DavieJ.; LacyP.Prevention of rejection of murine islet allografts by pretreatment with anti-dendritic cell antibody.Proc. Natl. Acad. Sci. USA81: 3864–3868; 1984.
22.
GillR.; HaoL.; LaffertyK.Antigen presentation and allo-immunity. In: NeubergerJ.; AdamsD., ed. Immunology of liver transplantation.London: Edward Arnold;1993: 115–126.
23.
GillR.; WolfL.; DanielD.; CoulombeM.CD4 T cells are both necessary and sufficient for islet xenograft rejection.Transplant. Proc.26: 1203; 1994.
24.
GillR.G.The role of direct and indirect antigen presentation in the response to islet xenografts.Transplant. Proc.24: 642–643; 1992.
25.
GillR.G.T-cell-T-cell collaboration in allograft responses.Curr. Opin. Immuno.5: 782–787; 1993.
26.
GillR.G.; CoulombeM.Rejection of pancreatic islet xenografts does not require CD8+ T-lymphocytes.Transplant. Proc.24: 2877–2878; 1992.
27.
GillR.G.; LaffertyK.J.The role of islet transplantation in the treatment of insulin-dependent diabetes mellitus.Imm. Aller. Clin. No. Am.9: 165–186; 1989.
28.
GoldingH.; SingerA.Role of accessory cell processing and presentation of shed H-2 alloantigens in allospecific cytotoxic T lymphocyte responses.J. Immunol.133: 597; 1984.
29.
GossJ.A.; NakafusaY.; FinkeE.H.; FlyeM.W.; LacyP.E.Induction of tolerance to islet xenografts in a concordant rat-to-mouse model.Diabetes43: 16–23; 1994.
30.
HaoL.; WangY.; GillR.G.; LaffertyK.J.Role of the L3T4+ T cell in allograft rejection.J. Immunol.139: 4022; 1987.
31.
HaoL.; WangY.; GillR.G.; LaRosaF.G.; TalmageD.W.; LaffertyK.J.Role of lymphokine in islet allograft rejection.Transplantation49: 609–614; 1990.
32.
HegreO.; HickeyG.; MarshallS.; SerieJ.Modification of allograft immunogenicity in perinatal islets isolated and purified in vitro.Transplantation37: 227–233; 1984.
33.
HullettD.A.; LandryA.S.; LeonardD.K.; SollingerH.W.Enhancement of thyroid allograft survival following organ culture.Transplantation47: 24; 1989.
34.
IldstadS.T.; SachsD.H.Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts.Nature307: 168–170; 1984.
35.
IrwinM.J.; HeathW.R.; ShermanL.A.Species-restricted interactions between CD8 and the α3 domain of class I influence the magnitude of the xenogeneic response.J. Exp. Med.170: 1091–1101; 1989.
JuneC.H.; LedbetterJ.A.; LinsleyP.S.; ThompsonC.B.Role of the CD28 receptor in T-cell activation.Immunol. Today11: 211–216; 1990.
38.
KalinkeU.; ArnoldB.; HammerlingG.J.Strong xenogeneic HLA response in transgenic mice after introducing an α3 domain into HLA B27.Nature348: 642–644; 1990.
39.
KamleN.K.; KlussmanK.; LinsleyP.S.; AruffoA.Differential costimulatory effects of adhesion molecules B7.; ICAM-1.; LFA-3.; VCAM-1 of resting and antigen-primed CD4+ T lymphocytes.J. Immunol.148: 1985–1992; 1992.
40.
La RosaF.Abrogation of mouse pancreatic islet allograft rejection by a four-day culture.Transplantation46: 330–333; 1988.
41.
La RosaF.; TalmageD.The abrogation of thyroid allograft rejection by culture in acid medium.Transplantation44: 592; 1987.
42.
La RosaF.G.; TalmageD.W.Major histocompatibility complex antigen expression on parenchymal cells of thyroid allografts is not by itself sufficient to induce rejection.Transplantation49: 605–609; 1990.
43.
LacyP.; DavieJ.; FinkeE.Prolongation of islet allograft survival following in vitro culture (24°C) and a single injection of ALS.Science204: 312–313; 1979.
44.
LacyP.; HegreO.; Gerasimidi-VazeouA.; GentileF.Maintenance of normoglycemia in diabetic mice by SC xenografts of encapsulated islets.Science254: 1782; 1991.
45.
LacyP.E.; RicordiC.; FinkeE.H.Effect of transplantation site and αL3T4 treatment on survival of rat, hamster, and rabbit islet xenografts in mice.Transplantation47: 761–766; 1989.
46.
LaffertyK.; BootesA.; DartG.; TalmageD.Effect of organ culture on the survival of thyroid allografts in mice.Transplantation22: 138–149; 1976.
47.
LaffertyK.J.; JonesM.A.S.Reactions of the graft-versus-host (GVH) type.Aust. J. Exp. Biol. Med. Sci.47: 17–54; 1969.
48.
LaffertyK.J.; ProwseS.J.; SimeonovicC.J.Immunobiology of tissue transplantation: A return to the passenger leukocyte concept.Annu. Rev. Immunol.1: 143–173; 1983.
49.
LaffertyK.J.; WarrenH.S.; WoolnoughJ.A.; TalmageD.W.Immunological induction of T lymphocytes: role of antigen and the costimulator.Blood Cells4: 395; 1978.
50.
LaffertyK.L.; CunninghamA.J.A new analysis of allogeneic interactions.Aust. J. Exp. Biol. Med. Sci.53: 27–42; 1975.
51.
LanzaR.; BeyerA.; KuhtreiberW.M.; ChickW.L.Humoral response to macroencapsulated porcine and canine islets.Abstract. Cell Transplant.3: 220; 1994.
52.
LauH.; ReemtsmaK.; HardyM.Prolongation of rat islet allograft survival by direct ultraviolet irradiation of the graft.Science223: 607–608; 1984.
53.
LenschowD.J.; ZengY.; ThistlethwaiteJ.R.; MontagA.; BradyW.; GibsonM.G.; LinsleyP.S.; BluestoneJ.A.Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig.Science257: 789–792; 1992.
54.
LinsleyP.S.; BradyW.; UrnesM.; GrosmaireL.; DamleN.K.; LedbetterJ.A.CTLA-4 is a second receptor for the B cell activation antigen B7.J. Exp. Med.174: 561–69; 1991.
55.
LoudovarisT.; CharltonG.; MandelT.T cells in the destruction of xenografts within cell impermeable membranes. Presented at the Second Int. Congress on Xenotransplantation 1993.
56.
LucasP.J.; ShearerG.M.; NeudorfS.; GressR.E.The human antimurine xenogeneic cytotoxic response I. Dependence on responder antigen-presenting cells.J. Immunol.144: 4548–4554; 1990.
57.
MandelT.E.; KoulmandaM.; LoudovarisT.; BaceljA.Islet grafts in NOD mice: A comparison of iso-, allo-, and pig xenografts.Transpl. Proc.21: 3813; 1989.
58.
MorrowC.; SutherlandD.; SteffesM.; NajarianJ.; BachF.Lack of donor-specific tolerance in mice with established anti-Ia-treated islet allografts.Transplantation36: 691–694; 1983.
59.
MosesR.D.; PiersonR.N.III; WinnH.J.; AuchinclossJ.H.Xenogeneic proliferation and lymphokine production are dependent on CD4+ helper T cells and self antigen-presenting cells in the mouse.J. Exp. Med.172: 567–575; 1990.
60.
MosesR.D.; WinnH.J.; AuchinclossH.J.Evidence that multiple defects in cell-surface molecule interactions across species differences are responsible for diminished xenogeneic T cell responses.Transplantation53: 203–209; 1992.
61.
O'SheaG.; SunA.Encapsulation of rat islets of Langerhans prolongs xenograft survival in diabetic mice.Diabetes35: 943–946; 1986.
62.
OsorioR.W.; AscherN.L.; StockP.G.Prolongation of in vivo mouse islet allograft survival by modulation of MHC class I antigen.Transplantation57: 783–788; 1994.
63.
PatelA.; HardyM.; Roy-ChoudhuryN.; WajsmanR.; SandovalM.; WilsonJ.; Roy-ChoudhuryJ.Long-term correction of genetic defect of liver function in rats by transplantation of liver cells after ultraviolet irradiation.Mol. Biol. Med.6: 187–196; 1989.
64.
PiersonR.N.III; WinnH.J.; RussellP.S.; AuchinclossH.Xenogeneic skin graft rejection is especially dependent on CD4+ T cells.J. Exp. Med.170: 991–996; 1989.
65.
PosseltA.M.; BarkerC.F.; TomaszewskiJ.E.; MarkmannJ.F.; ChotiM.A.; NajiA.Induction of donor-specific unresponsiveness by intrathymic islet transplantation.Science249: 1293–1295; 1990.
66.
RamrakhaP.; SharpR.; YeomanH.; StanleyM.The influence of MHC-compatible and MHC-incompatible antigen-presenting cells on the survival of MHC-compatible cultured murine keratinocyte allografts.Transplantation48: 676–680; 1989.
67.
RicordiC.; LacyP.E.; SterbenzK.; DavieJ.M.Low-temperature culture of human islets or in vivo treatment with L3T4 antibody produces a marked prolongation of islet human-to-mouse xenograft survival.Proc. Natl. Acad. Sci. USA84: 8080–8084; 1987.
68.
RosenbergA.; SingerA.Evidence that the effector mechanism of skin allograft rejection is antigen-specific.Proc. Natl. Acad. Sci. USA88: 7739–7742; 1988.
69.
SachsD.H.; BachF.H.Immunology of xenograft rejection.Human Immunology28: 245–251; 1990.
70.
SchwartzR.H.Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy.Cell71: 1065–1068; 1992.
71.
SerieJ.R.; HickeyG.E.; SchmittR.V.; HegreO.D.Prolongation of culture-isolated neonatal iselt xenografts without immunosuppression.Transplantation36: 6–11; 1983.
72.
ShizuruJ.A.; GregoryA.K.; ChaoC.T.B.; FathmanC.G.Islet allograft survival after a single course of treatment of recipient with antibody to L3T4.Science237: 278–280; 1987.
73.
SimeonovicC.J.; WilsonJ.D.CD4+ T-cell depletion in mice facilitates induction of tolerance to pig proislet xenografts: A comparison of NOD and CBA/H recipient models. Diab. Nutr.Metab.5(Suppl. 1): 133–138; 1992.
74.
SprentJ.; SchaeferM.Properties of purified T cells subsets. I. In vitro responses to class I vs. class II H-2 alloantigens.J. Exp. Med.162: 2068–2088; 1985.
75.
StockP.G.; AscherN.L.; ChenS.; FieldJ.; BachF.H.; SutherlandD.E.R.Evidence for direct and indirect pathways in the generation of the alloimmune response against pancreatic islets.Transplantation52: 704–709; 1991.
76.
SuttonR.; GrayD.W.R.; McShaneP.; DallmanM.J.; MorrisP.J.The specificity of rejection and the absence of susceptibility of pancreatic islet β cells to nonspecific immune destruction in mixed strain islets grafted beneath the renal capsule in the rat.J. Exp. Med.170: 751–762; 1989.
77.
SwainS.L.T cell subsets and the recognition of MHC class.Immunol. Rev.74: 129–142; 1983.
78.
TalmageD.; WoolnoughJ.; HemmingsenH.; LopezL.; LaffertyK.Activation of cytotoxic T cells by nonstimulating tumor cells and spleen cell factor(s).Proc. Natl. Acad. Sci. USA74: 1610–1614; 1977.
79.
VesoleD.; DartG.; TalmageD.Rejection of stable cultured allografts by active or passive (adoptive) immunization.Proc. Natl. Acad. Sci. USA79: 1626–1628; 1982.
80.
VignaliD.A.A.; MorenoJ.; SchillerD.; HammerlingG.J.Species-specific binding of CD4 to the β2 domain of major histocompatibility complex class II molecules.J. Exp. Med.175: 925–932; 1992.
81.
von HoegenP.; MiceliM.C.; TourvieilleB.; SchilhamM.; ParnesJ.R.Equivalence of human and mouse CD4 in enhancing antigen responses by a mouse class II-restricted T cell hybridoma.J. Exp. Med.170: 1879–1886; 1989.
82.
WangY.; HaoL.; GillR.G.; LaffertyK.J.Autoimmune diabetes in NOD mouse is L3T4 T-lymphocyte dependent.Diabetes36: 535; 1987.
83.
WangY.; PontesiliO.; GillR.G.; LaRosaF.G.; LaffertyK.J.The role of CD4+ and CD8+ T cells in the destruction of islet grafts by spontaneously diabetic mice.Proc. Natl. Acad. Sci. USA88: 527–531; 1991.
84.
WeckerH.; WinnH.; AuchinclossH.J.CD4+ T cells, without CD8+ or B lymphocytes, can reject xenogeneic skin grafts.Xenotransplantation1: 8–16; 1994.
WoolnoughJ.; MiskoI.; LaffertyK.J.Cytotoxic and proliferative lymphocyte responses to allogeneic and xenogeneic antigens in vitro.Aust. J. Exp. Bio. Med. Sci.57: 467–477; 1979.
87.
YoshizawaK.; YanoA.Mouse T lymphocytes proliferative responses specific for human MHC products in mouse anti-human xenogeneic MLR.J. Immunol.132: 2820–2829; 1984.
